Cargando…

Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis

BACKGROUND: Hormone receptor positive breast cancer is characterized by the potential for disease recurrence many years after initial diagnosis. Endocrine therapy has been shown to reduce the risk of such recurrence, but the optimal duration of endocrine therapy remains unclear. METHODS: We conducte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Mubarak, Mustafa, Tibau, Ariadna, Templeton, Arnoud J., Cescon, David W., Ocana, Alberto, Seruga, Bostjan, Amir, Eitan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3930532/ https://www.ncbi.nlm.nih.gov/pubmed/24586311 http://dx.doi.org/10.1371/journal.pone.0088238

Ejemplares similares

Clinical benefit of cancer drugs approved in Switzerland 2010–2019
por: Adam, Roman, et al.
Publicado: (2022)

Role of cooperative groups and funding source in clinical trials supporting guidelines for systemic therapy of breast cancer
por: Tibau, Ariadna, et al.
Publicado: (2018)

Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression
por: Templeton, Arnoud J., et al.
Publicado: (2016)

Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors: Systematic Review and Meta-Analysis
por: Ocana, Alberto, et al.
Publicado: (2014)

Efficacy, safety and tolerability of drugs studied in phase 3 randomized controlled trials in solid tumors over the last decade
por: Ribnikar, Domen, et al.
Publicado: (2021)

Associations between safety, tolerability, and toxicity and the reporting of health‐related quality of life in phase III randomized trials in common solid tumors
por: Saleh, Ramy R., et al.
Publicado: (2020)

Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel
por: Zist, Andrej, et al.
Publicado: (2015)

In silico analyses identify gene-sets, associated with clinical outcome in ovarian cancer: role of mitotic kinases
por: Ocaña, Alberto, et al.
Publicado: (2016)

Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses
por: Ocana, Alberto, et al.
Publicado: (2015)

Cardiovascular Toxicity of Multi-Tyrosine Kinase Inhibitors in Advanced Solid Tumors: A Population-Based Observational Study
por: Srikanthan, Amirrtha, et al.
Publicado: (2015)

Adjuvant tamoxifen for early breast cancer.
por: Smith, I.
Publicado: (1988)

Considerations for the clinical development of immuno-oncology agents in cancer
por: Pandiella, Atanasio, et al.
Publicado: (2023)

Association between PIK3CA activating mutations and outcomes in early-stage invasive lobular breast carcinoma treated with adjuvant systemic therapy
por: Ribnikar, Domen, et al.
Publicado: (2023)

Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis
por: Ethier, Josee-Lyne, et al.
Publicado: (2017)

Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations
por: Wilson, Brooke E., et al.
Publicado: (2021)

Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer
por: Aydiner, Adnan, et al.
Publicado: (2008)

Adjuvant tamoxifen for male breast cancer (MBC).
por: Ribeiro, G., et al.
Publicado: (1992)

Tamoxifen resistance and adjuvant hormone therapy
por: Howell, A
Publicado: (2005)

Association between control group therapy and magnitude of clinical benefit of cancer drugs
por: Molto, Consolacion, et al.
Publicado: (2022)

Controlled trial of tamoxifen as a single adjuvant agent in the management of early breast cancer. 'Nolvadex' Adjuvant Trial Organisation.
Publicado: (1988)

Neutrophils in cancer: prognostic role and therapeutic strategies
por: Ocana, Alberto, et al.
Publicado: (2017)

Adherence to Adjuvant Tamoxifen in Mexican Young Women with Breast Cancer
por: Martinez-Cannon, Bertha Alejandra, et al.
Publicado: (2021)

Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors
por: Uslu, Yasemin, et al.
Publicado: (2023)

Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials
por: Yan, Shunchao, et al.
Publicado: (2015)

Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer. CRC Adjuvant Breast Trial Working Party.
Publicado: (1988)

Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk
por: Pistilli, Barbara, et al.
Publicado: (2020)

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results
por: Ocaña, Alberto, et al.
Publicado: (2018)

CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
por: Province, M A, et al.
Publicado: (2014)

Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis
por: Goldvaser, Hadar, et al.
Publicado: (2019)

The Christie hospital adjuvant tamoxifen trial--status at 10 years.
por: Ribeiro, G., et al.
Publicado: (1988)

Granulosa cell tumor of the ovary and antecedent of adjuvant tamoxifen use for breast cancer
por: Abahssain, Halima, et al.
Publicado: (2010)

Radiation recall dermatitis induced by tamoxifen during adjuvant breast cancer treatment
por: Rhee, Jiyoung, et al.
Publicado: (2014)

Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells
por: Pinzón-García, Ana D., et al.
Publicado: (2021)

Adjuvant Aromatase Inhibitors or Tamoxifen Following Chemotherapy for Perimenopausal Breast Cancer Patients
por: Dackus, Gwen M H E, et al.
Publicado: (2021)

Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen—To Offer More? (aTTom) trial
por: Bartlett, J M S, et al.
Publicado: (2019)

Efficacy and Safety of the Addition of Internal Mammary Irradiation to Standard Adjuvant Radiation in Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis
por: Korzets, Yasmin, et al.
Publicado: (2022)

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex™ and Tamoxifen Alone or in Combination’ (ATAC) trial
por: Trialists' Group, The ATAC
Publicado: (2001)

First do no harm: extending the debate on the provision of preventive tamoxifen
por: Will, B P, et al.
Publicado: (2001)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen
por: van Nuland, M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ftuk7k1maaqpo6ec35d17ct06e